Figure 2.

VPA reactivates tumor-infiltrating immune cells.

Flow cytometric analyses of EL4 tumors from PBS- or VPA-treated tumor-bearing mice 14 days after EL4 inoculation. The proportion of (a) MDSCs (CD11b⁺Gr-1⁺), (b) TAMs (CD11b⁺Ly-6C⁻Ly-6G⁻F4/80⁺), (c) Tregs (CD4⁺CD8α⁻CD25⁺), (d) CD8⁺ T-cells (CD3ɛ⁺NK1.1⁻CD8α⁺), and (e) NK cells (CD3ɛ⁻NK1.1⁺) in total live cells are represented as means ± S.E.M, pooled from two (CD8⁺ T-cells, and NK cells) (n = 8–9), three (TAMs and Tregs) (n = 10–12), or four independent experiments (MDSCs) (n = 17). (*p < .05 by Student’s t test). (f) The proportion of CD69^hi cells in CD8⁺ T -cells (CD3ɛ⁺CD8α⁺CD4⁻) and NK cells (CD3ɛ⁻NK1.1⁺) was analyzed. Data represent one experiment representative of three independent experiment. FMO, fluorescence minus one